Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
01
Apr
Astellas Pharma Inc. JP3942400007
2026-03-31 Astellas Pharma Inc. “Announcement regarding top management personnel changes.”
31
Mar
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-03-30 Sumitomo Pharma Co.,Ltd. “Regarding the application for approval of a partial change in the dosage and administration of the atypical antipsychotic drug "Latuda" for pediatric use in schizophrenia in Japan.”
28
Mar
Otsuka Holdings Co.,Ltd. JP3188220002
2026-03-27 Otsuka Holdings Co.,Ltd. “The leukemia treatment drug "iclusig®" has applied for an additional indication in Japan for first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.”
28
Mar
Otsuka Holdings Co.,Ltd. JP3188220002
2026-03-27 Otsuka Holdings Co.,Ltd. “Announcement of changes to executive personnel.”
28
Mar
Eisai Co.,Ltd. JP3160400002
2026-03-27 Eisai Co.,Ltd. “The European Medicines Agency has accepted the marketing authorization application for the anticancer drug taretrectinib for the treatment of advanced ROS1-positive non-small cell lung cancer. This application will be reviewed for full approval according to the standard schedule. Applications are also planned in other licensed regions of Eisai, including the UK and Canada. Taretrectinib is already approved in the US, China, and Japan for the treatment of advanced ROS1-positive non-small cell lung cancer.”
28
Mar
Otsuka Holdings Co.,Ltd. JP3188220002
2026-03-27 Otsuka Holdings Co.,Ltd. “Regarding Otsuka Pharmaceutical's acquisition of Transcend Therapeutics.”
28
Mar
Shionogi & Co.,Ltd. JP3347200002
2026-03-27 Shionogi & Co.,Ltd. “Regarding the progress of the business improvement plan based on administrative guidance from the Ministry of Health, Labour and Welfare.”
28
Mar
Eisai Co.,Ltd. JP3160400002
2026-03-27 Eisai Co.,Ltd. “Regarding "Lenvima®" (lenvatinib), an application has been submitted in Japan to add a new dosage and administration method for combination therapy with "Wellig®" (verzutifan) for renal cell carcinoma that has progressed after cancer chemotherapy.”
28
Mar
Shionogi & Co.,Ltd. JP3347200002
2026-03-27 Shionogi & Co.,Ltd. “Regarding the conclusion of a bridge loan agreement for additional investment in ViiV Healthcare Ltd.”
27
Mar
Eisai Co.,Ltd. JP3160400002
2026-03-26 Eisai Co.,Ltd. “Notice Regarding the Selection of Directors Candidates.”
27
Mar
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-03-26 CHUGAI PHARMACEUTICAL CO.,LTD. “Regarding our thinking and policies on reducing the investment unit.”
27
Mar
Eisai Co.,Ltd. JP3160400002
2026-03-26 Eisai Co.,Ltd. “Eisai Co., Ltd.: Personnel changes and organizational restructuring.”
27
Mar
Shionogi & Co.,Ltd. JP3347200002
2026-03-26 Shionogi & Co.,Ltd. “Asahi Life Insurance has launched "TalkLab KIBIT," a conversational web application that uses AI analysis to determine "brain health," as part of its "Everyone's Peace of Mind 100-Year Project."”
26
Mar
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-03-25 Sumitomo Pharma Co.,Ltd. “Notice Regarding Recognition of Non-Operating Income in Our Standalone Financial Statements (Japanese GAAP).”
26
Mar
Eisai Co.,Ltd. JP3160400002
2026-03-25 Eisai Co.,Ltd. “We have released "Hibinoe," a parent-child dialogue facilitating app that supports preparation for future health risks of parents through family conversations—a family app that integrates "understanding the current state of the family, natural conversation, awareness of risks, and how to prepare."”
26
Mar
Otsuka Holdings Co.,Ltd. JP3188220002
2026-03-25 Otsuka Holdings Co.,Ltd. “OTSUKA Manga Healthy Library II: "Water is Amazing! ~The Power of Water for the Health of People and the Planet~" has been published and donated to all elementary schools nationwide.”
26
Mar
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-03-25 Sumitomo Pharma Co.,Ltd. “The "Extraordinary Report" has been published.”
25
Mar
Shionogi & Co.,Ltd. JP3347200002
2026-03-24 Shionogi & Co.,Ltd. “Announcement regarding the consolidation of Shionogi-Apnimed Sleep Science, LLC as a subsidiary.”
24
Mar
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-03-23 CHUGAI PHARMACEUTICAL CO.,LTD. “Notice Regarding the Discontinuation of Development of GYM329 (emugrobart) for Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy.”
24
Mar
Eisai Co.,Ltd. JP3160400002
2026-03-23 Eisai Co.,Ltd. “Analysis results on the long-term treatment continuation of "Rekenbi®" (lecanemab) in real-world clinical practice in the United States were presented at AD/PD™ 2026—analysis of "Rekenbi" real-world clinical data revealed the patient's choice to continue long-term treatment.”